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DivBACKGROUND In EVEREST II (Endovascular Valve Edge-to-Edge Repair Study), treatment of mitral regurgitation (MR)
with a novel percutaneous device showed superior safety compared with surgery, but less effective reduction in MR at
1 year.
OBJECTIVES This study sought to evaluate the ﬁnal 5-year clinical outcomes and durability of percutaneous mitral
valve (MV) repair with the MitraClip device compared with conventional MV surgery.
METHODS Patients with grade 3þ or 4þ MR were randomly assigned to percutaneous repair with the device or
conventional MV surgery in a 2:1 ratio (178:80). Patients prospectively consented to 5 years of follow-up.
RESULTS At 5 years, the rate of the composite endpoint of freedom from death, surgery, or 3þ or 4þ MR in the
as-treated population was 44.2% versus 64.3% in the percutaneous repair and surgical groups, respectively (p ¼ 0.01).
The difference was driven by increased rates of 3þ to 4þ MR (12.3% vs. 1.8%; p ¼ 0.02) and surgery (27.9% vs. 8.9%;
p ¼ 0.003) with percutaneous repair. After percutaneous repair, 78% of surgeries occurred within the ﬁrst 6 months.
Beyond 6 months, rates of surgery and moderate-to-severe MR were comparable between groups. Five-year mortality
rates were 20.8% and 26.8% (p ¼ 0.4) for percutaneous repair and surgery, respectively. In multivariable analysis,
treatment strategy was not associated with survival.
CONCLUSIONS Patients treated with percutaneous repair more commonly required surgery for residual MR during the
ﬁrst year after treatment, but between 1- and 5-year follow-up, comparably low rates of surgery for MV dysfunction with
either percutaneous or surgical therapy endorse the durability of MR reduction with both repair techniques. (EVEREST II
Pivotal Study High Risk Registry; NCT00209274) (J Am Coll Cardiol 2015;66:2844–54) © 2015 by the American College
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AB BR E V I A T I O N S
AND ACRONYM S
LV = left ventricular
LVEF = left ventricular
ejection fraction
MR = mitral regurgitation
MV = mitral valve
NYHA = New York Heart
Association
SLDA = single leaﬂet device
attachment
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2845T he MitraClip device (Abbott Vascular, MenloPark, California) was developed as a percuta-neous means to reduce mitral regurgitation
(MR) by approximating the mitral valve (MV) leaﬂets.
The procedure is modeled after the surgical Alﬁeri
double-oriﬁce technique of MV repair, which has
been shown to have durable results when performed
in conjunction with an annuloplasty ring for degener-
ative MR (1,2). We previously reported the results of
the randomized EVEREST II (Endovascular Valve
Edge-to-Edge Repair Study), in which percutaneous
MV repair using this percutaneous approach was
compared with conventional surgery (3–5). The pri-
mary outcome at 1 year demonstrated that conven-
tional surgery was more effective than percutaneous
repair for reducing MR. However, improvements in
left ventricular (LV) remodeling and clinical out-
comes were similar for both approaches and the
percutaneous approach demonstrated a greater level
of safety than did surgery (3).SEE PAGE 2855Several important clinical questions remain
unanswered regarding percutaneous MV repair for
moderate-to-severe MR. Given the increased preva-
lence of residual MR and the lack of annuloplasty
with this device, the durability of percutaneous
repair relative to conventional surgery, and the
impact of MV repair technique on long-term sur-
vival, symptoms, and LV remodeling, is unknown.
We sought to address these questions based on the
5-year, ﬁnal results of the EVEREST II randomized
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STUDY DESIGN AND ELIGIBILITY. EVEREST II
is a multicenter, randomized, nonblinded
trial of the MitraClip system compared with
conventional surgery for the treatment of MR
with pre-speciﬁed 5-year follow-up. Details of
the device, study design, and 1-year primary
endpoint analysis have been previously re-
ported (3,4). Brieﬂy, 279 patients were
enrolled at 37 study centers in North America
between September 2005 and November
2008. Eligible patients had moderate-to-severe (3þ) or
severe (4þ) chronic MR and were either symptomatic
with left ventricular ejection fraction (LVEF) >25%
and LV end-systolic diameter #55 mm or asymptom-
atic with 1 or more of the following: LVEF 25% to 60%,
LV end-systolic diameter $40 mm, new-onset atrial
ﬁbrillation, or pulmonary hypertension (pulmonary
artery systolic pressure >50 mm Hg at rest or
>60 mm Hg with exercise), all according to the
1998/2006 American College of Cardiology/American
Heart Association Joint Task Force recommendations
for surgical intervention for MR (6,7). Eligible patients
had to be candidates for mitral repair or replacement
surgery. Anatomic inclusion criteria required that
the primary regurgitant jet originated from mal-
coaptation of the A2 and P2 scallops of the MV.
Patients with both functional and degenerative MR
were included.
Baseline and follow-up echocardiograms were
assessed by an independent echocardiographic core
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2846MR was graded according to American Society of
Echocardiography guidelines (8). LV volumes and
ejection fraction were measured using the biplane
method of disks.
The study complied with the Declaration of Hel-
sinki regarding investigation in humans and was
conducted under an Investigational Device Exemp-
tion in the United States and Canada. The study was
approved by the institutional review boards at
participating sites. Written informed consent for 5
years of follow-up was obtained from all patients
before randomization.
The trial was designed by the sponsor, Abbott
Vascular, in collaboration with the investigators. The
Harvard Clinical Research Institute was contracted by
Abbott Vascular to perform data management, anal-
ysis, and clinical events adjudication. All authors had
access to all data.
STUDY PROCEDURE AND DEVICE. The percutaneous
procedure was performed with the patient under
general anesthesia using transesophageal echocardi-
ography and ﬂuoroscopic guidance in the cardiac
catheterization laboratory, as previously described
(3,9–11). Deployment of a second MitraClip device was
permitted if the ﬁrst did not result in an adequate
reduction in MR. If residual MR $3þ was determined
to be clinically unacceptable, the patient could un-
dergo either a second procedure to place the second
device or elective MV surgery. Patients were treated
with aspirin, 325 mg daily, for 6 months and clopi-
dogrel, 75 mg daily, for 30 days.
ENDPOINTS. We compared treatment groups using
the following endpoints through 5 years within the
all-treated cohort: 1) freedom from death, surgery for
MV dysfunction, and 3þ and 4þ MR; 2) freedom from
death; 3) freedom from surgery for MV dysfunction;
and 4) freedom from death and surgery for MV
dysfunction. Additional pre-speciﬁed analyses in-
clude change in LV dimensions and volumes, New
York Heart Association (NYHA) classiﬁcation of heart
failure (12), and 36-item short-form health survey
quality-of-life score (13). Clinical and echocardio-
graphic follow-up weremandated annually for 5 years.
All components of the primary safety and effective-
ness endpoints were adjudicated by members of an
independent clinical events committee or the core
echocardiographic laboratory.
STATISTICAL ANALYSIS. Comparisons were de-
signed and powered with pre-speciﬁed effectiveness
and safety margins. Surgery was expected to result in
more complete MR reduction; however, percutaneous
treatment was anticipated to have signiﬁcantly lower
procedural risk. Comparisons were performed withinthe all-treated cohort, which excludes patients who
were randomized but not treated, to avoid bias to-
ward the null. Results from the intention-to-treat
cohort are presented in Online Table 1.
The Student t test was used for analyses of
continuous variables and Fisher exact test for cate-
gorical variables. Because “freedom from 3þ and 4þ”
is not amenable to time-to-event analyses, we also
used Fisher exact test to compare the primary
endpoint, its components, and other binary vari-
ables. Time-to-event curves were constructed using
Kaplan–Meier estimates, which were compared using
the log-rank test. To study the effect of risk factors on
5-year mortality, Cox proportional-hazards regression
was performed. To evaluate for heterogeneity of the
treatment effect on the composite effectiveness
endpoint at 5 years, we performed tests for interac-
tion with treatment using the following post-hoc
subgroups: sex, age <70 versus $70 years, MR etiol-
ogy (degenerative vs. functional), and LVEF (<60%
vs. $60%). No adjustments were made for multiple
testing. All statistical analyses were performed using
SAS version 9.3 (SAS Institute, Cary, North Carolina).
RESULTS
We randomly assigned 279 patients from 37 sites
between September 2005 and November 2008 in a 2:1
ratio to percutaneous (n ¼ 184) or surgical (n ¼ 95)
treatment of MR. Of these patients, 6 and 15 patients
in the device and surgery arms, respectively, were
randomized but not treated, resulting in 178 and 80
patients in each arm comprising the all-treated cohort
that serves as the basis of this analysis. Final 5-year
follow-up was completed on November 11, 2013.
Twenty-four patients in each arm were excluded from
this analysis as detailed in Figure 1. The 5-year anal-
ysis of the all-treated cohort therefore included 154
(87%) and 56 (70%) patients in the device and surgical
arms, respectively. Baseline clinical characteristics
were well-balanced across treatment groups (Table 1).
Ninety patients (50.6%) were treated with a single
MitraClip device and 68 patients (38.2%) received
2 devices during the index procedure. The study de-
vice was not deployed in the remaining 20 (11.2%)
patients.
As previously reported, single leaﬂet device
detachment (SLDA) was observed in 9 patients within
the ﬁrst year of follow-up (3). One additional patient
experienced late SLDA approximately 14 months after
the percutaneous repair. All patients with SLDA sub-
sequently underwent MV surgery (5 replacement,
5 repair). There were no cases of device embolization
through 5-year follow-up. A single case of mitral
FIGURE 1 Study Flow: All-Treated Group
279 patients underwent randomization
184 patients were assigned
to percutaneous repair group
95 patients were assigned to
surgery group
6 patients were randomized to the
group but not treated
15 patients were randomized to the
group but not treated
All-Treated Cohort
178 patients 80 patients underwent mitralvalve surgery
24 patients were excluded:
    — 3 missed the 5-year visit
    — 5 completed the 5-year visit
        but had missing or
        un-evaluable MR grade
    — 16 withdrew consent
24 patients were excluded:
    — 2 missed the 5-year visit
    — 7 completed the 5-year
        visit but had missing or
        un-evaluable MR grade
    — 15 withdrew consent
154 (87%) were included in
the 5-year analysis
56 (70%) were included in
the 5-year analysis
Data are shown for patients in the all-treated cohort evaluated for the 5-year efﬁcacy endpoint. Because the primary endpoint required echocardiographic
assessment of mitral regurgitation (MR), patients with missing MR grade at 5-year follow-up were excluded from the analysis.
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2847stenosis, deﬁned as an MV area <1.5 cm2, was
observed after the index procedure before discharge;
the patient subsequently underwent MV replacement
surgery. There were no additional reports of mitral
stenosis through 5 years.
COMPARATIVE EFFECTIVENESS THROUGH 5 YEARS.
Freedom from death, surgery for MV dysfunction,
and 3þ and 4þ MR occurred at 5 years in 44.2% of
patients receiving percutaneous repair and in 64.3%
of those receiving surgery (p ¼ 0.01) (Table 2). There
was no signiﬁcant difference in mortality between
surgery and percutaneous repair at 5 years (20.8% vs.
26.8%; p ¼ 0.36) (Table 2); however, surgery or
reoperation was more frequent with percutaneous
repair (27.9% vs. 8.9%; p ¼ 0.003) as was 3þ or 4þMR
(12.3% vs. 1.8%; p ¼ 0.02) (Table 2). Clinical outcomes
within the intention-to-treat cohort are shown in
Online Table 1.
At 5 years, freedom from death and surgery for MV
dysfunction was 60.6% with the device versus 73.3%
in the surgery group (p ¼ 0.03) (Central Illustration).
An early hazard for surgery for MV dysfunction wasobserved after percutaneous repair; speciﬁcally, 78%
of surgeries (33 of 43) occurred by 6-month follow-up.
Beyond 6 months through 5 years, there was no dif-
ference in the rate of freedom from surgery for MV
dysfunction (77.7% with percutaneous repair vs.
76.2% with surgery; p ¼ 0.77) (Central Illustration).
Survivors in both groups demonstrated signiﬁcant
reduction in MR from baseline to 12 months (paired
p < 0.001 for both groups) and from baseline to
5 years (paired p < 0.001 for both groups), demon-
strating the durability of MV repair with both the
surgical and the percutaneous approaches. As pre-
viously reported, surgery proved to be more effec-
tive at 12 months because fewer patients had 3þ or
4þ MR after surgery than after percutaneous repair
(0% vs. 17.9%; p ¼ 0.004). This difference remained
at 5-year follow-up (2.5% vs. 18.8%; p ¼ 0.01)
(Figure 2A).
Despite increased MR reduction with surgery,
NYHA functional class III/IV symptoms were more
frequently experienced at 12 months with surgery
compared with percutaneous repair (7.5% vs. 1.0%;
p ¼ 0.03) (Figure 2B). At 5 years, a nonsigniﬁcant
TABLE 1 Baseline Characteristics: All-Treated Cohort
Percutaneous Repair Surgery
Age, yrs 67.0  12.7 (178) 64.7  12.6 (80)
Female 36.5 (65/178) 33.8 (27/80)
Comorbidities
Congestive heart failure 90.4 (161/178) 80.0 (64/80)
Atrial ﬁbrillation 32.9 (56/170) 38.7 (29/75)
Coronary artery disease 46.9 (83/177) 43.8 (35/80)
Myocardial infarction 21.5 (38/177) 21.5 (17/79)
Coronary artery bypass graft 20.8 (37/178) 16.3 (13/80)
Previous percutaneous intervention 23.7 (42/177) 16.3 (13/80)
Hypercholesterolemia 60.2 (106/176) 68.4 (54/79)
Hypertension 72.5 (129/178) 82.5 (66/80)
Diabetes mellitus 7.9 (14/178) 8.8 (7/80)
COPD 15.3 (27/177) 13.8 (11/80)
LVEF, % 59.9  10.1 (176) 61.3  10.7 (80)
NYHA functional class
I 9.6 (17/178) 17.5 (14/80)
II 40.4 (72/178) 32.5 (26/80)
III 43.8 (78/178) 45.0 (36/80)
IV 6.2 (11/178) 5.0 (4/80)
MR severity
0: none 0.0 (0/178) 0.0 (0/80)
1þ: mild 0.0 (0/178) 0.0 (0/80)
1þ to 2þ: mild to moderate 0.0 (0/178) 1.3 (1/80)
2þ: moderate 3.9 (7/178) 6.3 (5/80)
3þ: moderate to severe 71.9 (128/178) 70.0 (56/80)
4þ: severe 24.2 (43/178) 22.5 (18/80)
Regurgitant volume, ml/beat 42.3  23.4 (169) 46.5  26.7 (73)
Regurgitant oriﬁce area, cm2 0.55  0.36 (166) 0.60  0.36 (73)
MR etiology
Functional 27.0 (48/178) 22.5 (18/80)
Degenerative 73.0 (130/178) 77.5 (62/80)
Degenerative with anterior/bileaﬂet ﬂail/prolapse 32.6 (58/178) 27.5 (22/80)
Degenerative with posterior ﬂail/prolapse 37.6 (67/178) 47.5 (38/80)
Degenerative with neither ﬂail nor prolapse 2.8 (5/178) 2.5 (2/80)
Values are mean  SD (N) or % (n/N).
COPD ¼ chronic obstructive pulmonary disease; LVEF ¼ left ventricular ejection fraction; MR ¼ mitral
regurgitation; NYHA ¼ New York Heart Association.
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percutaneous repair patients and 2.5% of surgery
patients were classiﬁed as having NYHA functional
class III or IV symptoms (p ¼ 0.19).TABLE 2 All-Treated Cohort: Efﬁcacy Endpoint and Components at 5
5 Years
Percutaneous
Repair (n ¼ 154)
Surge
(n ¼ 5
Freedom from death, MV surgery,
or reoperation, and 3þ or 4þ MR
44.2 (68) 64.3 (3
Death 20.8 (32) 26.8 (1
MV surgery or reoperation 27.9 (43) 8.9 (5
3þ or 4þ MR 12.3 (19) 1.8 (1
Values are % (n). *Includes patients that completed the 5-year visit and had MR grade
MR ¼ mitral regurgitation; MV ¼ mitral valve.LV REMODELING. As previously reported, signiﬁcant
improvements in LV dimensions were observed after
both percutaneous and surgical management of MR at
1- and 4-year follow-up (3,5). LV end-diastolic volume
continued to improve between 1 and 5 years after
percutaneous MV repair (Table 3). A small increase in
LV internal diastolic diameter was observed late after
both percutaneous repair and surgery, and LV internal
diastolic diameter was signiﬁcantly smaller at 1 and
5 years with surgery compared with percutaneous
repair (Table 3). LVEF decreased slightly beyond 1 year
after percutaneous MV repair, but the overall decre-
ment in LV systolic function was comparable between
arms and largely attributable to greater reduction in
LV end-diastolic versus end-systolic volumes.
Systolic septal-lateral annular dimension was
equivalent at baseline, but smaller at 5 years after
surgery compared with device. Importantly, systolic
septal-lateral annular dimension remained unchanged
from baseline to 1 year and from 1 to 5 years among
device-treated patients despite the lack of annulo-
plasty. After surgery, systolic septal-lateral annular
dimension decreased signiﬁcantly from baseline to
1-year follow-up but then increased beyond 1 year.
Diastolic septal-lateral annular dimension improved
by 1 year but remained stable thereafter in both treat-
ment arms.
At 1 year, treatment effect heterogeneity was
observed in age and etiology of MR subgroups, with a
trend suggesting heterogeneity based on LVEF as well
(3,5). In relation to freedom from death, surgery for
MV dysfunction, and 3þ and 4þ MR at 5 years, sig-
niﬁcant subgroup interactions persisted between pa-
tients who were $70 and <70 years of age, such that
surgery performed better than percutaneous repair in
younger patients (interaction p ¼ 0.005) (Table 4).
Similar to what was seen at 1 year, surgery was su-
perior to percutaneous repair in patients with
degenerative MR at 5 years (interaction p ¼ 0.02);
efﬁcacy, however, was comparable across groups in
those with functional MR. Additionally, a signiﬁcantYears*
5 Years if Event-Free at 1 Year
ry
6) p Value
Percutaneous
Repair (n ¼ 87)
Surgery
(n ¼ 48) p Value
6) 0.01 69.0 (60) 75.0 (36) 0.55
5) 0.36 16.1 (14) 16.7 (8) >0.99
) 0.003 5.7 (5) 6.3 (3) >0.99
) 0.02 11.5 (10) 2.1 (1) 0.10
available or died or had MV surgery before withdrawal from the study.
CENTRAL ILLUSTRATION 5-Year Clinical Outcomes: Percutaneous Repair and Surgery for Mitral Regurgitation
Feldman, T. et al. J Am Coll Cardiol. 2015; 66(25):2844–54.
Kaplan-Meier curves depict (A) freedom from the composite of death, mitral valve (MV) surgery, or reoperation, (B) freedom from death, (C) freedom from MV surgery
or reoperation, and (D) landmark analysis of freedom from MV surgery or reoperation beyond 6 months after percutaneous repair or surgery. Although patients
undergoing percutaneous repair more commonly required surgery for residual mitral regurgitation during the ﬁrst year after treatment, comparably low rates of surgery
for MV dysfunction with either percutaneous or surgical therapy were seen between 1- and 5-year follow-up. RCT ¼ randomized clinical trial.
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2849interaction with LVEF was observed with superior
results seen with surgery in those with LVEF $60%
(interaction p ¼ 0.04).
PREDICTORS OF 5-YEAR MORTALITY. Within pooled
analyses of the entire all-treated population, uni-
variable logistic regression identiﬁed several pre-
dictors of 5-year mortality (Table 5). Predictors
consisted largely of established clinical risk factorsand comorbid conditions including older age; dia-
betes; hypertension; moderate-to-severe renal dis-
ease; chronic obstructive pulmonary disease;
established coronary artery, peripheral artery, or ce-
rebrovascular disease; low LVEF; atrial ﬁbrillation;
prior myocardial infarction; and prior cardiac surgery.
Functional MR etiology and higher NYHA functional
class portended worse 5-year survival. Treatment
strategy (percutaneous repair or surgery) did not
FIGURE 2 Severity of MR and Heart Failure Symptoms Post-Treatment
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For patients who survived to 5 years and had pertinent data reported at each time point,
comparisons are seen for (A) echocardiographic severity of MR in 101 and 40 patients
in the device and surgery arms, respectively, and (B) New York Heart Association functional
class in 105 and 40 patients in the device and surgery arms, respectively. MR ¼ mitral
regurgitation.
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able analyses identiﬁed functional MR, chronic
obstructive pulmonary disease, older age, diabetes,
and peripheral artery disease as independent pre-
dictors of 5-year mortality (Table 5).
DISCUSSION
The EVEREST II randomized trial evaluated the safety
and efﬁcacy of percutaneous MV repair using the
MitraClip device relative to standard MV surgery
(3,4). The 1-year primary analyses demonstrated that
percutaneous MV repair was less effective than sur-
gery in reducing MR but that safety with the device
was superior to surgery, that LV dimensions and
volumes decreased after both percutaneous repair
and surgery, and that both techniques similarlyrelieve clinical symptoms and improve quality of life
(3). Taken together with data from the EVEREST II
High Risk Registry, REALISM (Real-world Continued
Access registry), and the growing European experi-
ence with percutaneous repair (14–16), the short-term
safety of this percutaneous approach has been clear
as has its efﬁcacy in reducing MR, although to a lesser
degree than surgery.
The primary ﬁnding of the EVEREST II 5-year
follow-up is the durability of MR reduction with this
device. Despite early imbalance in rates of 3þ or 4þ
MR and of subsequent surgery for MV dysfunction,
few patients (n ¼ 10 of 43) experienced worsening MR
or surgery after 6-month follow-up. In addition, even
when there was more severe residual MR after device
placement, there was no difference in long-term
survival after percutaneous repair compared with
surgery (Central Illustration) and no decrement in LV
systolic function. Supplementing these observations
was the persistent reduction in symptoms and LV
dimensions at 5 years. The percutaneous approach
proved to be safe during follow-up with only 1 case of
late (>1 year) SLDA and no reported episodes of de-
vice embolization.
Because intrinsic MV pathology in those with
degenerative MR does not respond to medical ther-
apy, degenerative MR patients at prohibitive risk for
surgery have no alternative treatment options. The
favorable safety proﬁle of this device was believed
to be a reasonable option for such patients. Based on
the experience to date and the observed superiority
of surgery for MR reduction in EVEREST II (3), the
U.S. Food and Drug Administration approved the
MitraClip device in October 2013 for the reduction of
“symptomatic MR $3þ due to primary abnormality
of the mitral apparatus (degenerative MR) in pa-
tients who have been determined to be at prohibi-
tive risk for MV surgery by a heart team” (17).
Because this approved device is now used in routine
clinical practice, it has become important to describe
its long-term safety and efﬁcacy. This report of the
ﬁnal 5-year results of EVEREST II support the dura-
bility of MR reduction observed after successful de-
vice implantation and resultant symptom alleviation
and LV reverse remodeling, endorse the long-term
safety of this approach, and refute concerns that
greater residual MR after percutaneous repair results
in reduced long-term survival.
Our ﬁndings suggest that the mechanical reduc-
tion of MR with percutaneous repair using this
device is durable beyond 6 months. Additionally,
because MR was reduced to a lesser extent following
percutaneous repair compared with surgery, it is
also an important ﬁnding that residual low-grade MR
TABLE 3 Left Ventricular Dimensions by Echocardiography*
Measure-Matched
Analysis
Percutaneous
Repair Surgery
Difference
(Percutaneous
Repair-Surgery) (95% CI) p Value
Baseline
LVEDV, ml 158.1  35.9 (98) 155.7  44.3 (38) 2.4 (-12.1 to 16.9) 0.74
LVESV, ml 61.3  20.1 (98) 58.3  26.7 (38) 3.1 (-5.3 to 11.4) 0.53
LVIDd, cm 5.5  0.6 (101) 5.5  0.7 (41) 0.1 (-0.2 to 0.3) 0.54
LVIDs, cm 3.6  0.9 (99) 3.4  0.8 (41) 0.2 (-0.1 to 0.5) 0.13
LVEF, % 61.5  7.9 (98) 63.2  10.3 (38) -1.7 (-4.9 to 1.6) 0.37
SLAD diastolic 3.9  0.6 (80) 3.9  0.5 (8) 0.0 (-0.4 to 0.4) 0.94
SLAD systolic 3.3  0.6 (80) 3.3  0.5 (8) 0.0 (-0.5 to 0.4) 0.92
1 Year
Change From
Baseline
to 1 Year
p Value for
Paired
Comparison
Change From
Baseline
to 1 Year
p Value for
Paired
Comparison
LVEDV, ml 133.7  32.3 (98) -24.4  2.7 <0.0001 113.5  38.8 (38) -42.2  6.0 <0.0001 20.3 (7.3 to 33.2) 0.002
LVESV, ml 56.8  21.3 (98) -4.5  1.4 0.0017 51.4  26.8 (38) -6.9  3.2 0.04 5.4 (-3.2 to 14.1) 0.22
LVIDd, cm 5.1  0.6 (101) -0.4  0.0 <0.0001 4.8  0.8 (41) -0.7  0.1 <0.0001 0.3 (0.1 to 0.6) 0.02
LVIDs, cm 3.5  0.7 (99) -0.1  0.1 0.06 3.3  0.8 (41) -0.1  0.1 0.14 0.2 (-0.1 to 0.5) 0.10
LVEF, % 58.2  8.1 (98) -3.3  0.7 <0.0001 56.3  9.8 (38) -6.9  1.6 0.0001 2.0 (-1.3 to 5.2) 0.24
SLAD diastolic 3.8  0.4 (80) 0.0  0.1 0.46 3.2  0.4 (8) -0.6  0.2 0.01 0.6 (0.3 to 1.0) <0.001
SLAD systolic 3.3  0.4 (80) -0.1  0.1 0.02 2.7  0.4 (8) -0.7  0.2 0.002 0.6 (0.3 to 0.9) <0.001
5 Year
Change From
1 to 5 Years
Change From
1 to 5 Years
NYHA functional
class I or II
91.4 (96/105) 97.5 (39/40) 0.19
LVEDV, ml 128.5  32.4 (98) -5.2  2.3 0.02 112.6  38.8 (38) -0.9  3.1 0.77 15.9 (3.0 to 28.9) 0.02
LVESV, ml 57.2  23.3 (98) 0.4  1.5 0.78 50.2  27.0 (38) -1.2  2.1 0.57 7.1 (-2.2 to 16.3) 0.13
LVIDd, cm 5.3  0.7 (101) 0.1  0.0 0.0004 4.9  0.7 (41) 0.1  0.1 0.05 0.3 (0.1 to 0.6) 0.009
LVIDs, cm 3.6  0.9 (99) 0.1  0.1 0.06 3.3  0.9 (41) 0.1  0.1 0.40 0.3 (-0.1 to 0.6) 0.09
LVEF, % 56.4  10.2 (98) -1.8  0.8 0.03 56.9  9.5 (38) 0.7  1.2 0.59 -0.5 (-4.3 to 3.3) 0.79
SLAD diastolic 3.9  0.5 (80) 0.0  0.1 0.61 3.7  0.4 (8) 0.2  0.1 0.07 0.3 (-0.1 to 0.6) 0.14
SLAD systolic 3.3  0.5 (80) 0.1  0.1 0.08 3.0  0.3 (8) 0.5  0.2 0.02 0.4 (0.0 to 0.7) 0.03
Values are mean  SD (n) or % (n/N), unless otherwise indicated. *Includes patients with each echocardiographic measure at all time points.
CI ¼ conﬁdence interval; LVEDV¼ left ventricular end-diastolic volume; LVESV¼ left ventricular end-systolic volume; LVIDd¼ left ventricular internal diameter in diastole; LVIDs¼ left ventricular internal
diameter in diastole; SLAD ¼ septal-lateral annular dimension; other abbreviations as in Table 1.
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2851was not associated with either worsening MR or
progressive LV dilation. Rather, LV dimensions and
volumes and septal-lateral dimensions were compa-
rable following percutaneous repair and surgery at
5 years. Reasons for these favorable results may
include tethering of the annulus from the tissue
bridge that forms between the anterior and posterior
mitral leaﬂets caused by the device implant, result-
ing in preserved septal-lateral annular dimension,
and overall maintenance of the geometry of the
ventricle.
The landmark analysis of this device demonstrated
that the clinical failures primarily occurred within the
ﬁrst 6 months, most of which were caused by inade-
quate MR reduction during the index procedure or
early SLDA. Failure to implant a device occurred in
9.5% and SLDA in 6.3% of procedures in this trial.
The EVEREST II trial was performed early during
the global experience with this ﬁrst-in-class newtechnology, and both the acute procedure success
rates and SLDA rates have improved signiﬁcantly in
recently reported registry experiences (15,18). Not
surprisingly, there has been a signiﬁcant learning
curve, with contemporary acute procedure success
rates exceeding 95% in most reports, and SLDA rates
of 1% in more recent series (15,18,19).
Treatment effect heterogeneity was observed on
the basis of age, etiology of MR, and LVEF such that
patients with age $70 years, functional MR, or
LVEF <60% had similar outcomes with percutaneous
repair versus surgery. The complex interplay between
the mitral apparatus, concurrent coronary artery
disease, and/or cardiomyopathy in functional MR,
more prevalent in elderly subjects, results in a clinical
challenge for which treatment options are limited
(20,21). An efﬁcacious percutaneous treatment op-
tion, such as the one studied here, for these high-risk
patients is appealing; however, it remains unclear
TABLE 5 Baseline Pr
Moderate-to-severe re
COPD
Functional MR
LVEF, %
Myocardial infarction
Age, yrs
NYHA functional class
Coronary artery disease
Peripheral artery disea
Prior cardiac surgery
Atrial ﬁbrillation
Diabetes mellitus
Cerebrovascular diseas
Hypertension
Hypercholesterolemia
Stroke
Male
BMI (<25.6 vs. $25.6
White
Baseline 4þ MR
Percutaneous repair vs
*Stepwise model with p va
BMI ¼ body mass index;
TABLE 4 Subgroup Analyses for Freedom From Death, MV Surgery or Reoperation, and 3þ or 4þ MR at 5 Years
Subgroup
Percutaneous
Repair Surgery Difference (95% CI) p value
Interaction
p value
Sex 0.89
Male 42.9 (42/98) 63.9 (23/36) -21.0% (-39.5% to -2.5%) 0.03
Female 46.4 (26/56) 65.0 (13/20) -18.6% (-43.2% to 6.1%) 0.15
Age 0.005
Age $70 yrs 45.1 (32/71) 42.3 (11/26) 2.8% (-19.5% to 25.0%) 0.81
Age <70 yrs 43.4 (36/83) 83.3 (25/30) -40.0% (-57.0% to -22.9%) <0.001
Type of MR 0.02
Functional MR 40.5 (17/42) 28.6 (4/14) 11.9% (-16.0% to 39.8%) 0.43
Degenerative MR 45.5 (51/112) 76.2 (32/42) -30.7% (-46.5% to -14.8%) <0.001
LVEF 0.04
LVEF <60% 44.1 (26/59) 41.2 (7/17) 2.9% (-23.7% to 29.5%) 0.83
LVEF $60% 44.1 (41/93) 74.4 (29/39) -30.3% (-47.3% to -13.3%) 0.001
Values are % (n/N) unless otherwise indicated.
Abbreviations as in Table 1.
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2852whether either surgery or percutaneous repair are
superior to optimal medical therapy alone. The efﬁ-
cacy of this device compared with optimal medical
therapy for functional MR is the focus of the ongoingedictors of 5-Year Mortality
Univariable Multivariable*
HR (95% CI) p Value HR (95% CI) p Value
nal disease 12.7 (5.2–30.6) <0.001
4.5 (2.5–8.2) <0.001 2.9 (1.5–5.6) 0.001
4.2 (2.4–7.4) <0.001 2.7 (1.4–5.0) 0.003
0.95 (0.93–0.97) <0.001
3.8 (2.1–6.8) <0.001
1.1 (1.0–1.1) <0.001 1.1 (1.0–1.1) <0.001
III/IV 4.5 (2.2–9.0) <0.001
3.9 (2.0–7.6) <0.001
se 3.9 (1.9–7.9) <0.001 2.1 (0.99–4.5) 0.05
2.7 (1.5–4.8) <0.001
2.5 (1.4–4.6) 0.003
3.2 (1.5–6.8) 0.003 2.3 (1.0–5.1) 0.05
e 2.8 (1.3–6.3) 0.01
3.0 (1.2–7.6) 0.02
1.9 (1.0–3.8) 0.06
2.8 (0.69–11.8) 0.15
0.8 (0.46–1.5) 0.54
kg/m2) 1.2 (0.67–2.1) 0.55
0.8 (0.33–1.8) 0.57
0.84 (0.42–1.7) 0.63
. surgery 0.94 (0.51–1.7) 0.85
lue of entry of 0.20 and p value to stay of 0.10.
HR ¼ hazard ratio; other abbreviations as in Tables 1 and 3.COAPT (Cardiovascular Outcomes Assessment of the
MitraClip Percutaneous Therapy for Heart Failure
Patients with Functional Mitral Regurgitation) trial.
Long-term survival in the EVEREST II trial was
similar between treatment arms, yet functional MR
and advanced age remained important predictors of
decreased survival, regardless of percutaneous or
surgical treatment. Thus, although MV repair may
improve symptoms, the mortality risk associated with
functional MR may be related to underlying comorbid
conditions leading to LV dilation and not to the MR
per se, as has been shown previously (22).
Prior surgical series have reported reoperation
rates of 3% per year in patients with degenerative MR,
similar to the rate seen in the surgical arm of this
study (23). Although most historical surgical reports
tend to be single-center, retrospective, self-reported,
and without the use of core laboratory echocardio-
graphic review, the prospective nature of this trial
helped clearly deﬁne the reoperation rate.
STUDY LIMITATIONS. The randomized comparison of
percutaneous repair versus surgery, the use of an
echocardiographic core laboratory, the prospective
5-year follow-up, and the independent adjudication
of clinical events are major strengths of the EVEREST
II trial; however, several limitations must be consid-
ered. The EVEREST II trial was an open-label study
and more patients within the surgical arm withdrew
from the study before undergoing MV surgery.
Therefore, to better estimate the impact of each
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Although mitral
valve repair surgery is superior to percutaneous mitral valve
intervention using the MitraClip device in reducing the severity of
MR, the device reduces symptoms, produces durable reduction
of MR, and promotes favorable reverse remodeling of the left
ventricle 5 years after intervention.
TRANSLATIONALOUTLOOK: Despite reduction in MR severity
either by surgery or deployment of the device, patients with func-
tional MR face an increased long-term risk of mortality, and further
studies are needed to determine whether either of these interven-
tions improves survival compared with optimal medical therapy
alone.
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2853intervention, we opted to analyze the all-treated
comparison even though doing so diminished some
beneﬁts of randomization. LVEF was well-preserved
in the EVEREST II cohort, even among patients with
functional MR, making inferences regarding MitraClip
outcomes in patients with functional MR and severely
depressed LV function difﬁcult. Also, data on
septal-lateral annular dimensions after surgery and
results of subgroup analyses regarding MR etiology,
speciﬁcally in demonstrating areas of potential equi-
poise between surgery and percutaneous repair,
should be considered exploratory given the relatively
small sample size within these subgroups of patients.
It should be noted that the population we studied
included both degenerative and functional MR, and is
distinct from the populations that are being treated in
global practice, those who are the subject of the
COAPT trial, and those for whom MitraClip has been
approved in the United States.
CONCLUSIONS
The ﬁnal 5-year results of the EVEREST II trial sup-
ported the superiority of surgery in reducing MR but
clearly supported the long-term safety of the Mitra-
Clip and the durability of MR reduction after percu-
taneous repair. Beyond 1 year, worsening MR and
surgery for MV dysfunction occurred rarely after
either surgery or percutaneous repair. Similarly, im-
provements in heart failure symptoms and in LV di-
mensions remained stable through 5-year follow-up,
mitigating concerns that residual MR after deviceplacement and the absence of an annuloplasty ring
with the device would result in progressive wors-
ening of MR and LV dilation. Finally, despite reduc-
tion of MR with either percutaneous repair or surgery,
functional MR portended increased risk of long-term
mortality. Whether reduction of MR in such patients
prolongs survival remains to be determined within
the ongoing COAPT trial.
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